Clinical Trial Update: Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol [Phase 2]

View source ↗

Summary

Phase 2 study evaluating RAD001 (everolimus) in advanced cholangiocarcinoma (RADiChol) is listed with unknown status; sponsor is Austin Health.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• RAD001 (Everolimus) (everolimus)

Snippet

Sponsor: Austin Health | Conditions: Cholangiocarcinoma | Phase 2 | Status: UNKNOWN